Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04184271 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of Advantage Arrest
A Phase 2 study, sponsored by Advantage Silver Dental Arrest.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04184271: Completed Phase 2 study, sponsored by Advantage Silver Dental Arrest.
NCT04184271 is a Phase 2 study that has completed, run by Advantage Silver Dental Arrest. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04184271, a Phase 2 study, has completed, sponsored by Advantage Silver Dental Arrest.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study aim is to characterize the kinetics of silver and fluoride after topical application of silver diamine fluoride.
Primary Outcome
24 hour fluoride urinary recovery (in mg)
Interventions
- DRUG 38% silver diamine fluoride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2019-03-31 |
| Phase | Phase 2 |
What the finished NCT04184271 record still lists
NCT04184271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which 38% silver diamine fluoride is the first listed.
NCT04184271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04184271 about?
NCT04184271 is a clinical study titled "Pharmacokinetics of Advantage Arrest". The study aim is to characterize the kinetics of silver and fluoride after topical application of silver diamine fluoride.
What is the current status of trial NCT04184271?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-08-01. Estimated completion is 2019-03-31.
What interventions are being tested in trial NCT04184271?
The interventions under investigation include: 38% silver diamine fluoride (DRUG).
Who is sponsoring clinical trial NCT04184271?
This trial is sponsored by Advantage Silver Dental Arrest, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04184271's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI